Celltrion

Historical price data

Celltrion is a global biopharmaceutical company headquartered in South Korea that specializes in the development, manufacturing, and commercialization of biosimilar and innovative biologics. The company operates Korea's largest global R&D center and was the first in Asia to operate US FDA cGMP certified animal cell culture facilities. With direct sales networks across major global markets including the US and Europe, Celltrion has established itself as the No. 1 manufacturer and exporter of biosimilars in Korea. The company recently acquired a former Eli Lilly facility in Branchburg, New Jersey to establish local US manufacturing capabilities.

Large-scale biologics manufacturing using animal cell culture technology with world-class production capabilities and quality control systems meeting US FDA and European EMA cGMP standards. The company operates integrated facilities for monoclonal antibody development and biosimilar manufacturing.

93 drugs in pipeline, 35 in Phase 3

Total raised: $900M

Celltrion competes as the leading biosimilar manufacturer in Korea against major international biosimilar companies and original biologics manufacturers. The company differentiates through its vertically integrated business model, first-mover advantage in Asia for FDA-certified manufacturing, and established direct sales networks in major global markets.